Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: Multivariate logistic regression analysis and factor analysis

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2349-2355

  Juutilainen, Auni ^a,b   Hämäläinen, Sari ^b   Pulkki, Kari ^a   Kuittinen, Taru ^b   Nousiainen, Tapio ^b   Jantunen, Esa ^a,b   Koivula, Irma ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bacteremia; Biomarker; C reactive protein; Neutropenic fever; Procalcitonin; Sepsis

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FIBRINOGEN; HYDROCORTISONE; IDARUBICIN; LACTIC ACID; MELPHALAN; PROCALCITONIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HODGKIN DISEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS;

ADOLESCENT; ADULT; AGED; BACTEREMIA; BIOLOGICAL MARKERS; FACTOR ANALYSIS, STATISTICAL; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUTROPENIA; SEPSIS; YOUNG ADULT;

EID: 82255163481     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.597904     Document Type: Article

References (31)

1. Gencer S, Salepci T, Ozer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J Infect 2003;47:65-72. (Pubitemid 36850138)
2. Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 2009;101 (Suppl. 1):S6-S10.
3. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009;101(Suppl. 1):S11-S14.
4. Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer 2009;101(Suppl. 1):S23-S26.
5. Hämäläinen S, Kuittinen T, Matinlauri I, et al. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma 2008;49:495-501. (Pubitemid 351298333)
6. Hämäläinen S, Kuittinen T, Matinlauri I, et al. Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome. Scand J Infect Dis 2009;41:14-20.
7. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596. (Pubitemid 43810035)
8. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.
9. Shapiro NI, Schuetz P, Yano K, et al. Te association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010;14:R182.
10. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008;29:328-333. (Pubitemid 351271703)
11. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009;37:96-104.
12. Karlsson S, Heikkinen M, Pettilä V, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010;14:R205.
13. Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-1642. (Pubitemid 39050511)
14. Schmit X, Vincent JL. Te time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008;36:213-219.
15. von Lilienfeld-Toal M, Schneider A, Orlopp K, et al. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 2006; 14:1241-1245. (Pubitemid 44810851)
16. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005;128:2864-2875. (Pubitemid 41507648)
17. Sakr Y, Sponholz C, Tuche F, et al. Te role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36:396-407.
18. Persson L, Engervall P, Magnuson A, et al. Use of inf ammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004;36:365-371. (Pubitemid 38967694)
19. Yonemori K, Kanda Y, Yamamoto R, et al. Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. Leuk Lymphoma 2001;41:607-614. (Pubitemid 32717313)
20. Hughes W T, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751. (Pubitemid 34194843)
21. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Def nitions Conference. Intensive Care Med 2003;29:530-538. (Pubitemid 36523666)
22. Bone RC, Balk RA, Cerra FB, et al. Def nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Te ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009;136(5 Suppl.):e28.
23. Comrey AL. A first course in factor analysis. New York: Academic Press, Inc.; 1973.
24. Charles PE, Ladoire S, Aho S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 2008;8:38.
25. Hämäläinen S, Juutilainen A, Kuittinen T, et al. Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein. Leuk Lymphoma 2010;51:1040-1046.
26. Juutilainen A, Hämäläinen S, Matinlauri I, et al. Serial plasma lactate measurements in haematological patients with neutropenic fever. Scand J Infect Dis 2010;42:102-108.
27. Matinlauri I, Juutilainen A, Hämäläinen S, et al. Fibrinogen and antithrombin in hematological patients with neutropenic fever. CEJMed 2010;5:520-526.
28. Koivula I, Hämäläinen S, Jantunen E, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis 2011;43:471-478.
29. Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008;49:1752-1761.
30. Jeddi R, Achour M, Amor RB, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 2010;15:28-32.
31. Miedema KG, de Bont ES, Elferink RF, et al. Te diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2010 Aug 28. Epub ahead of print.